Early Therapy Evaluation of Combined Cetuximab and Irinotecan in Orthotopic Pancreatic Tumor Xenografts by Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Early pancreatic cancer response following cetuximab and/or irinotecan therapies was measured by serial dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) before and during therapy. Groups 1 to 4 ( n = 6/group) of SCID mice bearing orthotopic pancreatic adenocarcinoma xenografts expressi...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2011-05-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.2310/7290.2010.00040 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832544501820817408 |
|---|---|
| author | Hyunki Kim Karri D. Folks Lingling Guo Jeffery C. Sellers Naomi S. Fineberg Cecil R. Stockard William E. Grizzle Donald J. Buchsbaum Desiree E. Morgan James F. George Kurt R. Zinn |
| author_facet | Hyunki Kim Karri D. Folks Lingling Guo Jeffery C. Sellers Naomi S. Fineberg Cecil R. Stockard William E. Grizzle Donald J. Buchsbaum Desiree E. Morgan James F. George Kurt R. Zinn |
| author_sort | Hyunki Kim |
| collection | DOAJ |
| description | Early pancreatic cancer response following cetuximab and/or irinotecan therapies was measured by serial dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) before and during therapy. Groups 1 to 4 ( n = 6/group) of SCID mice bearing orthotopic pancreatic adenocarcinoma xenografts expressing luciferase were treated with phosphate-buffered saline, cetuximab, irinotecan, or cetuximab combined with irinotecan, respectively, twice weekly for 3 weeks. DCE-MRI was performed on days 0, 1, 2, and 3 after therapy initiation, whereas anatomic magnetic resonance imaging was performed on days 0, 1, 2, 3, 6, and 13. Bioluminescence imaging was performed on days 0 and 21. At day 21, all tumors were collected for further histologic analyses (Ki-67 and CD31 staining), whereas tumor dimensions were measured by calipers. The K trans values in the 0.5 mm–thick peripheral tumor region were calculated, and the changes in K trans during the 3 days posttherapy were compared to tumor volume changes, bioluminescent signal changes, and histologic findings. The K trans changes in the peripheral tumor region after 3 days of therapy were linearly correlated with 21-day decreases in tumor volume ( p < .001), bioluminescent signal ( p = .050), microvessel densities ( p = .002), and proliferating cell densities ( p = .001). This study supports the clinical use of DCE-MRI for pancreatic cancer patients for early assessment of an anti–epidermal growth factor receptor therapy combined with chemotherapy. |
| format | Article |
| id | doaj-art-a1eb7222d69b43a3aaa0faae80ea31c1 |
| institution | Kabale University |
| issn | 1536-0121 |
| language | English |
| publishDate | 2011-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj-art-a1eb7222d69b43a3aaa0faae80ea31c12025-02-03T10:12:57ZengSAGE PublishingMolecular Imaging1536-01212011-05-011010.2310/7290.2010.0004010.2310_7290.2010.00040Early Therapy Evaluation of Combined Cetuximab and Irinotecan in Orthotopic Pancreatic Tumor Xenografts by Dynamic Contrast-Enhanced Magnetic Resonance ImagingHyunki KimKarri D. FolksLingling GuoJeffery C. SellersNaomi S. FinebergCecil R. StockardWilliam E. GrizzleDonald J. BuchsbaumDesiree E. MorganJames F. GeorgeKurt R. ZinnEarly pancreatic cancer response following cetuximab and/or irinotecan therapies was measured by serial dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) before and during therapy. Groups 1 to 4 ( n = 6/group) of SCID mice bearing orthotopic pancreatic adenocarcinoma xenografts expressing luciferase were treated with phosphate-buffered saline, cetuximab, irinotecan, or cetuximab combined with irinotecan, respectively, twice weekly for 3 weeks. DCE-MRI was performed on days 0, 1, 2, and 3 after therapy initiation, whereas anatomic magnetic resonance imaging was performed on days 0, 1, 2, 3, 6, and 13. Bioluminescence imaging was performed on days 0 and 21. At day 21, all tumors were collected for further histologic analyses (Ki-67 and CD31 staining), whereas tumor dimensions were measured by calipers. The K trans values in the 0.5 mm–thick peripheral tumor region were calculated, and the changes in K trans during the 3 days posttherapy were compared to tumor volume changes, bioluminescent signal changes, and histologic findings. The K trans changes in the peripheral tumor region after 3 days of therapy were linearly correlated with 21-day decreases in tumor volume ( p < .001), bioluminescent signal ( p = .050), microvessel densities ( p = .002), and proliferating cell densities ( p = .001). This study supports the clinical use of DCE-MRI for pancreatic cancer patients for early assessment of an anti–epidermal growth factor receptor therapy combined with chemotherapy.https://doi.org/10.2310/7290.2010.00040 |
| spellingShingle | Hyunki Kim Karri D. Folks Lingling Guo Jeffery C. Sellers Naomi S. Fineberg Cecil R. Stockard William E. Grizzle Donald J. Buchsbaum Desiree E. Morgan James F. George Kurt R. Zinn Early Therapy Evaluation of Combined Cetuximab and Irinotecan in Orthotopic Pancreatic Tumor Xenografts by Dynamic Contrast-Enhanced Magnetic Resonance Imaging Molecular Imaging |
| title | Early Therapy Evaluation of Combined Cetuximab and Irinotecan in Orthotopic Pancreatic Tumor Xenografts by Dynamic Contrast-Enhanced Magnetic Resonance Imaging |
| title_full | Early Therapy Evaluation of Combined Cetuximab and Irinotecan in Orthotopic Pancreatic Tumor Xenografts by Dynamic Contrast-Enhanced Magnetic Resonance Imaging |
| title_fullStr | Early Therapy Evaluation of Combined Cetuximab and Irinotecan in Orthotopic Pancreatic Tumor Xenografts by Dynamic Contrast-Enhanced Magnetic Resonance Imaging |
| title_full_unstemmed | Early Therapy Evaluation of Combined Cetuximab and Irinotecan in Orthotopic Pancreatic Tumor Xenografts by Dynamic Contrast-Enhanced Magnetic Resonance Imaging |
| title_short | Early Therapy Evaluation of Combined Cetuximab and Irinotecan in Orthotopic Pancreatic Tumor Xenografts by Dynamic Contrast-Enhanced Magnetic Resonance Imaging |
| title_sort | early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast enhanced magnetic resonance imaging |
| url | https://doi.org/10.2310/7290.2010.00040 |
| work_keys_str_mv | AT hyunkikim earlytherapyevaluationofcombinedcetuximabandirinotecaninorthotopicpancreatictumorxenograftsbydynamiccontrastenhancedmagneticresonanceimaging AT karridfolks earlytherapyevaluationofcombinedcetuximabandirinotecaninorthotopicpancreatictumorxenograftsbydynamiccontrastenhancedmagneticresonanceimaging AT linglingguo earlytherapyevaluationofcombinedcetuximabandirinotecaninorthotopicpancreatictumorxenograftsbydynamiccontrastenhancedmagneticresonanceimaging AT jefferycsellers earlytherapyevaluationofcombinedcetuximabandirinotecaninorthotopicpancreatictumorxenograftsbydynamiccontrastenhancedmagneticresonanceimaging AT naomisfineberg earlytherapyevaluationofcombinedcetuximabandirinotecaninorthotopicpancreatictumorxenograftsbydynamiccontrastenhancedmagneticresonanceimaging AT cecilrstockard earlytherapyevaluationofcombinedcetuximabandirinotecaninorthotopicpancreatictumorxenograftsbydynamiccontrastenhancedmagneticresonanceimaging AT williamegrizzle earlytherapyevaluationofcombinedcetuximabandirinotecaninorthotopicpancreatictumorxenograftsbydynamiccontrastenhancedmagneticresonanceimaging AT donaldjbuchsbaum earlytherapyevaluationofcombinedcetuximabandirinotecaninorthotopicpancreatictumorxenograftsbydynamiccontrastenhancedmagneticresonanceimaging AT desireeemorgan earlytherapyevaluationofcombinedcetuximabandirinotecaninorthotopicpancreatictumorxenograftsbydynamiccontrastenhancedmagneticresonanceimaging AT jamesfgeorge earlytherapyevaluationofcombinedcetuximabandirinotecaninorthotopicpancreatictumorxenograftsbydynamiccontrastenhancedmagneticresonanceimaging AT kurtrzinn earlytherapyevaluationofcombinedcetuximabandirinotecaninorthotopicpancreatictumorxenograftsbydynamiccontrastenhancedmagneticresonanceimaging |